nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—lung cancer—thymus cancer	0.847	1	CtDrD
Gefitinib—Ischaemia—Octreotide—thymus cancer	0.00521	0.0773	CcSEcCtD
Gefitinib—Rectal disorder—Octreotide—thymus cancer	0.00387	0.0575	CcSEcCtD
Gefitinib—Appetite absent—Octreotide—thymus cancer	0.00382	0.0567	CcSEcCtD
Gefitinib—Anorectal disorder—Octreotide—thymus cancer	0.00361	0.0536	CcSEcCtD
Gefitinib—Nail disorder—Octreotide—thymus cancer	0.00293	0.0435	CcSEcCtD
Gefitinib—Seborrhoeic dermatitis—Octreotide—thymus cancer	0.00279	0.0414	CcSEcCtD
Gefitinib—Acne—Octreotide—thymus cancer	0.00226	0.0335	CcSEcCtD
Gefitinib—Drug interaction—Octreotide—thymus cancer	0.00205	0.0304	CcSEcCtD
Gefitinib—Cystitis noninfective—Octreotide—thymus cancer	0.00186	0.0275	CcSEcCtD
Gefitinib—Cystitis—Octreotide—thymus cancer	0.00183	0.0272	CcSEcCtD
Gefitinib—SBK1—pituitary gland—thymus cancer	0.00178	0.0288	CbGeAlD
Gefitinib—Mouth ulceration—Octreotide—thymus cancer	0.00172	0.0255	CcSEcCtD
Gefitinib—Bladder pain—Octreotide—thymus cancer	0.00172	0.0255	CcSEcCtD
Gefitinib—Thrombophlebitis—Octreotide—thymus cancer	0.00159	0.0236	CcSEcCtD
Gefitinib—CHEK2—pituitary gland—thymus cancer	0.00155	0.0251	CbGeAlD
Gefitinib—SBK1—thyroid gland—thymus cancer	0.00154	0.0248	CbGeAlD
Gefitinib—CHEK2—bone marrow—thymus cancer	0.00134	0.0217	CbGeAlD
Gefitinib—CHEK2—thyroid gland—thymus cancer	0.00134	0.0216	CbGeAlD
Gefitinib—IRAK4—hematopoietic system—thymus cancer	0.00131	0.0211	CbGeAlD
Gefitinib—Dehydration—Octreotide—thymus cancer	0.00128	0.019	CcSEcCtD
Gefitinib—ERBB3—hematopoietic system—thymus cancer	0.00128	0.0207	CbGeAlD
Gefitinib—Dry skin—Octreotide—thymus cancer	0.00126	0.0188	CcSEcCtD
Gefitinib—MKNK2—hematopoietic system—thymus cancer	0.00122	0.0197	CbGeAlD
Gefitinib—IRAK1—hematopoietic system—thymus cancer	0.00122	0.0197	CbGeAlD
Gefitinib—CHEK2—lung—thymus cancer	0.00122	0.0196	CbGeAlD
Gefitinib—MKNK1—hematopoietic system—thymus cancer	0.0012	0.0194	CbGeAlD
Gefitinib—ERBB3—epithelium—thymus cancer	0.00117	0.0189	CbGeAlD
Gefitinib—Pancreatitis—Octreotide—thymus cancer	0.00117	0.0173	CcSEcCtD
Gefitinib—MKNK2—epithelium—thymus cancer	0.00111	0.018	CbGeAlD
Gefitinib—Weight decreased—Octreotide—thymus cancer	0.00108	0.016	CcSEcCtD
Gefitinib—Pneumonia—Octreotide—thymus cancer	0.00107	0.0159	CcSEcCtD
Gefitinib—Conjunctivitis—Octreotide—thymus cancer	0.00103	0.0153	CcSEcCtD
Gefitinib—Haematuria—Octreotide—thymus cancer	0.00101	0.015	CcSEcCtD
Gefitinib—Hepatobiliary disease—Octreotide—thymus cancer	0.00101	0.0149	CcSEcCtD
Gefitinib—Epistaxis—Octreotide—thymus cancer	0.001	0.0149	CcSEcCtD
Gefitinib—MAP3K19—lung—thymus cancer	0.000991	0.016	CbGeAlD
Gefitinib—STK10—hematopoietic system—thymus cancer	0.00099	0.016	CbGeAlD
Gefitinib—CSNK1E—pituitary gland—thymus cancer	0.000984	0.0159	CbGeAlD
Gefitinib—IRAK4—pituitary gland—thymus cancer	0.000969	0.0156	CbGeAlD
Gefitinib—SBK1—lymph node—thymus cancer	0.000954	0.0154	CbGeAlD
Gefitinib—Hepatitis—Octreotide—thymus cancer	0.000954	0.0142	CcSEcCtD
Gefitinib—Oedema peripheral—Octreotide—thymus cancer	0.00094	0.014	CcSEcCtD
Gefitinib—MKNK2—cardiac atrium—thymus cancer	0.000924	0.0149	CbGeAlD
Gefitinib—IRAK4—lymphoid tissue—thymus cancer	0.000919	0.0148	CbGeAlD
Gefitinib—MKNK1—cardiac atrium—thymus cancer	0.000913	0.0147	CbGeAlD
Gefitinib—MKNK2—pituitary gland—thymus cancer	0.000903	0.0146	CbGeAlD
Gefitinib—ERBB3—lymphoid tissue—thymus cancer	0.000901	0.0146	CbGeAlD
Gefitinib—MKNK1—pituitary gland—thymus cancer	0.000891	0.0144	CbGeAlD
Gefitinib—Cardiac disorder—Octreotide—thymus cancer	0.000885	0.0131	CcSEcCtD
Gefitinib—EGFR—thyroid gland—thymus cancer	0.000882	0.0142	CbGeAlD
Gefitinib—MKNK2—lymphoid tissue—thymus cancer	0.000857	0.0138	CbGeAlD
Gefitinib—Arrhythmia—Octreotide—thymus cancer	0.000852	0.0127	CcSEcCtD
Gefitinib—CSNK1E—thyroid gland—thymus cancer	0.000848	0.0137	CbGeAlD
Gefitinib—MKNK1—lymphoid tissue—thymus cancer	0.000846	0.0137	CbGeAlD
Gefitinib—Alopecia—Octreotide—thymus cancer	0.000843	0.0125	CcSEcCtD
Gefitinib—IRAK4—bone marrow—thymus cancer	0.000837	0.0135	CbGeAlD
Gefitinib—IRAK4—thyroid gland—thymus cancer	0.000835	0.0135	CbGeAlD
Gefitinib—CHEK2—lymph node—thymus cancer	0.000831	0.0134	CbGeAlD
Gefitinib—Malnutrition—Octreotide—thymus cancer	0.000831	0.0123	CcSEcCtD
Gefitinib—ERBB3—thyroid gland—thymus cancer	0.000818	0.0132	CbGeAlD
Gefitinib—EGFR—lung—thymus cancer	0.000801	0.0129	CbGeAlD
Gefitinib—MKNK2—bone marrow—thymus cancer	0.00078	0.0126	CbGeAlD
Gefitinib—IRAK1—bone marrow—thymus cancer	0.00078	0.0126	CbGeAlD
Gefitinib—MKNK2—thyroid gland—thymus cancer	0.000778	0.0126	CbGeAlD
Gefitinib—IRAK1—thyroid gland—thymus cancer	0.000778	0.0126	CbGeAlD
Gefitinib—CSNK1E—lung—thymus cancer	0.00077	0.0124	CbGeAlD
Gefitinib—MKNK1—bone marrow—thymus cancer	0.00077	0.0124	CbGeAlD
Gefitinib—MKNK1—thyroid gland—thymus cancer	0.000768	0.0124	CbGeAlD
Gefitinib—Anaemia—Octreotide—thymus cancer	0.000768	0.0114	CcSEcCtD
Gefitinib—IRAK4—lung—thymus cancer	0.000758	0.0122	CbGeAlD
Gefitinib—Malaise—Octreotide—thymus cancer	0.000749	0.0111	CcSEcCtD
Gefitinib—ERBB3—lung—thymus cancer	0.000743	0.012	CbGeAlD
Gefitinib—Cough—Octreotide—thymus cancer	0.000725	0.0108	CcSEcCtD
Gefitinib—ORM1—hematopoietic system—thymus cancer	0.000718	0.0116	CbGeAlD
Gefitinib—MKNK2—lung—thymus cancer	0.000707	0.0114	CbGeAlD
Gefitinib—IRAK1—lung—thymus cancer	0.000707	0.0114	CbGeAlD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.000702	0.0104	CcSEcCtD
Gefitinib—MKNK1—lung—thymus cancer	0.000698	0.0113	CbGeAlD
Gefitinib—STK10—lymphoid tissue—thymus cancer	0.000697	0.0113	CbGeAlD
Gefitinib—Dry mouth—Octreotide—thymus cancer	0.000692	0.0103	CcSEcCtD
Gefitinib—Infection—Octreotide—thymus cancer	0.000673	0.01	CcSEcCtD
Gefitinib—MAP2K5—cardiac atrium—thymus cancer	0.000671	0.0108	CbGeAlD
Gefitinib—Shock—Octreotide—thymus cancer	0.000667	0.0099	CcSEcCtD
Gefitinib—Nervous system disorder—Octreotide—thymus cancer	0.000665	0.00987	CcSEcCtD
Gefitinib—Thrombocytopenia—Octreotide—thymus cancer	0.000664	0.00985	CcSEcCtD
Gefitinib—Skin disorder—Octreotide—thymus cancer	0.000658	0.00977	CcSEcCtD
Gefitinib—MAP2K5—pituitary gland—thymus cancer	0.000656	0.0106	CbGeAlD
Gefitinib—Anorexia—Octreotide—thymus cancer	0.000646	0.00959	CcSEcCtD
Gefitinib—STK10—bone marrow—thymus cancer	0.000634	0.0102	CbGeAlD
Gefitinib—STK10—thyroid gland—thymus cancer	0.000633	0.0102	CbGeAlD
Gefitinib—Dyspnoea—Octreotide—thymus cancer	0.000604	0.00897	CcSEcCtD
Gefitinib—Decreased appetite—Octreotide—thymus cancer	0.000589	0.00875	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Octreotide—thymus cancer	0.000585	0.00869	CcSEcCtD
Gefitinib—Fatigue—Octreotide—thymus cancer	0.000584	0.00867	CcSEcCtD
Gefitinib—Constipation—Octreotide—thymus cancer	0.00058	0.0086	CcSEcCtD
Gefitinib—Pain—Octreotide—thymus cancer	0.00058	0.0086	CcSEcCtD
Gefitinib—STK10—lung—thymus cancer	0.000575	0.00928	CbGeAlD
Gefitinib—MAP2K5—thyroid gland—thymus cancer	0.000565	0.00913	CbGeAlD
Gefitinib—Gastrointestinal pain—Octreotide—thymus cancer	0.000554	0.00823	CcSEcCtD
Gefitinib—EGFR—lymph node—thymus cancer	0.000548	0.00885	CbGeAlD
Gefitinib—Urticaria—Octreotide—thymus cancer	0.000538	0.00799	CcSEcCtD
Gefitinib—Body temperature increased—Octreotide—thymus cancer	0.000536	0.00795	CcSEcCtD
Gefitinib—Abdominal pain—Octreotide—thymus cancer	0.000536	0.00795	CcSEcCtD
Gefitinib—CSNK1E—lymph node—thymus cancer	0.000527	0.00851	CbGeAlD
Gefitinib—IRAK4—lymph node—thymus cancer	0.000519	0.00838	CbGeAlD
Gefitinib—MAP2K5—lung—thymus cancer	0.000513	0.00829	CbGeAlD
Gefitinib—ERBB3—lymph node—thymus cancer	0.000508	0.00821	CbGeAlD
Gefitinib—CYP2C19—hematopoietic system—thymus cancer	0.000507	0.00818	CbGeAlD
Gefitinib—Hypersensitivity—Octreotide—thymus cancer	0.000499	0.00741	CcSEcCtD
Gefitinib—Asthenia—Octreotide—thymus cancer	0.000486	0.00722	CcSEcCtD
Gefitinib—MKNK2—lymph node—thymus cancer	0.000483	0.00781	CbGeAlD
Gefitinib—IRAK1—lymph node—thymus cancer	0.000483	0.00781	CbGeAlD
Gefitinib—Pruritus—Octreotide—thymus cancer	0.00048	0.00712	CcSEcCtD
Gefitinib—MKNK1—lymph node—thymus cancer	0.000477	0.00771	CbGeAlD
Gefitinib—Diarrhoea—Octreotide—thymus cancer	0.000464	0.00688	CcSEcCtD
Gefitinib—ORM1—bone marrow—thymus cancer	0.00046	0.00743	CbGeAlD
Gefitinib—Vomiting—Octreotide—thymus cancer	0.000431	0.0064	CcSEcCtD
Gefitinib—Rash—Octreotide—thymus cancer	0.000427	0.00634	CcSEcCtD
Gefitinib—Dermatitis—Octreotide—thymus cancer	0.000427	0.00634	CcSEcCtD
Gefitinib—ORM1—lung—thymus cancer	0.000417	0.00673	CbGeAlD
Gefitinib—CYP1A1—hematopoietic system—thymus cancer	0.000408	0.00659	CbGeAlD
Gefitinib—Nausea—Octreotide—thymus cancer	0.000403	0.00598	CcSEcCtD
Gefitinib—CYP3A5—hematopoietic system—thymus cancer	0.000399	0.00645	CbGeAlD
Gefitinib—STK10—lymph node—thymus cancer	0.000393	0.00635	CbGeAlD
Gefitinib—CYP2C9—hematopoietic system—thymus cancer	0.000393	0.00634	CbGeAlD
Gefitinib—CYP1A1—epithelium—thymus cancer	0.000373	0.00603	CbGeAlD
Gefitinib—MAP2K5—lymph node—thymus cancer	0.000351	0.00567	CbGeAlD
Gefitinib—ABCG2—pituitary gland—thymus cancer	0.000319	0.00515	CbGeAlD
Gefitinib—CYP1A1—cardiac atrium—thymus cancer	0.00031	0.00501	CbGeAlD
Gefitinib—CYP3A4—hematopoietic system—thymus cancer	0.0003	0.00484	CbGeAlD
Gefitinib—CYP2D6—hematopoietic system—thymus cancer	0.000295	0.00476	CbGeAlD
Gefitinib—ORM1—lymph node—thymus cancer	0.000285	0.0046	CbGeAlD
Gefitinib—ABCG2—bone marrow—thymus cancer	0.000276	0.00445	CbGeAlD
Gefitinib—ABCG2—thyroid gland—thymus cancer	0.000275	0.00444	CbGeAlD
Gefitinib—CYP1A1—thyroid gland—thymus cancer	0.000261	0.00422	CbGeAlD
Gefitinib—ALB—lymph node—thymus cancer	0.00025	0.00404	CbGeAlD
Gefitinib—ABCG2—lung—thymus cancer	0.00025	0.00403	CbGeAlD
Gefitinib—CYP1A1—lung—thymus cancer	0.000237	0.00383	CbGeAlD
Gefitinib—CYP3A5—lung—thymus cancer	0.000232	0.00374	CbGeAlD
Gefitinib—ABCB1—hematopoietic system—thymus cancer	0.000212	0.00342	CbGeAlD
Gefitinib—ABCB1—epithelium—thymus cancer	0.000194	0.00313	CbGeAlD
Gefitinib—ABCG2—lymph node—thymus cancer	0.000171	0.00276	CbGeAlD
Gefitinib—CYP1A1—lymph node—thymus cancer	0.000162	0.00262	CbGeAlD
Gefitinib—ABCB1—pituitary gland—thymus cancer	0.000157	0.00254	CbGeAlD
Gefitinib—ABCB1—lymphoid tissue—thymus cancer	0.000149	0.00241	CbGeAlD
Gefitinib—ABCB1—bone marrow—thymus cancer	0.000136	0.00219	CbGeAlD
Gefitinib—ABCB1—thyroid gland—thymus cancer	0.000136	0.00219	CbGeAlD
Gefitinib—ABCB1—lung—thymus cancer	0.000123	0.00199	CbGeAlD
Gefitinib—ABCB1—lymph node—thymus cancer	8.42e-05	0.00136	CbGeAlD
Gefitinib—ERBB3—Signaling Pathways in Glioblastoma—TP53—thymus cancer	8.08e-05	0.00344	CbGpPWpGaD
Gefitinib—IRAK1—IL-1 signaling pathway—AKT1—thymus cancer	7.82e-05	0.00333	CbGpPWpGaD
Gefitinib—IRAK1—p75(NTR)-mediated signaling—TP53—thymus cancer	7.72e-05	0.00329	CbGpPWpGaD
Gefitinib—MKNK1—MAPK Signaling Pathway—TP53—thymus cancer	7.68e-05	0.00327	CbGpPWpGaD
Gefitinib—CHEK2—Integrated Breast Cancer Pathway—TP53—thymus cancer	7.59e-05	0.00323	CbGpPWpGaD
Gefitinib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—thymus cancer	7.59e-05	0.00323	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CYLD—thymus cancer	7.48e-05	0.00318	CbGpPWpGaD
Gefitinib—MKNK1—Disease—MAML2—thymus cancer	7.38e-05	0.00314	CbGpPWpGaD
Gefitinib—IRAK4—Toll-like Receptor Signaling Pathway—AKT1—thymus cancer	7.19e-05	0.00306	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways in Glioblastoma—AKT1—thymus cancer	7.08e-05	0.00301	CbGpPWpGaD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—thymus cancer	7.03e-05	0.00299	CbGpPWpGaD
Gefitinib—MAP2K5—MicroRNAs in cardiomyocyte hypertrophy—AKT1—thymus cancer	6.94e-05	0.00295	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling by NGF—KIT—thymus cancer	6.83e-05	0.0029	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways in Glioblastoma—AKT1—thymus cancer	6.82e-05	0.0029	CbGpPWpGaD
Gefitinib—MKNK1—Signaling by FGFR—AKT1—thymus cancer	6.68e-05	0.00284	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by NGF—KIT—thymus cancer	6.58e-05	0.0028	CbGpPWpGaD
Gefitinib—ERBB3—Constitutive PI3K/AKT Signaling in Cancer—AKT1—thymus cancer	6.57e-05	0.00279	CbGpPWpGaD
Gefitinib—IRAK1—p75(NTR)-mediated signaling—AKT1—thymus cancer	6.52e-05	0.00277	CbGpPWpGaD
Gefitinib—MKNK1—MAPK Signaling Pathway—AKT1—thymus cancer	6.49e-05	0.00276	CbGpPWpGaD
Gefitinib—EGFR—Signaling by SCF-KIT—KIT—thymus cancer	6.45e-05	0.00274	CbGpPWpGaD
Gefitinib—CHEK2—Integrated Breast Cancer Pathway—AKT1—thymus cancer	6.41e-05	0.00273	CbGpPWpGaD
Gefitinib—CHEK2—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	6.29e-05	0.00268	CbGpPWpGaD
Gefitinib—EGFR—ErbB Signaling Pathway—TP53—thymus cancer	6.28e-05	0.00267	CbGpPWpGaD
Gefitinib—MKNK1—Signaling by FGFR in disease—AKT1—thymus cancer	6.22e-05	0.00265	CbGpPWpGaD
Gefitinib—IRAK1—Apoptosis Modulation and Signaling—TP53—thymus cancer	6.19e-05	0.00263	CbGpPWpGaD
Gefitinib—EGFR—Downstream signaling of activated FGFR—KIT—thymus cancer	6.17e-05	0.00263	CbGpPWpGaD
Gefitinib—EGFR—a6b1 and a6b4 Integrin signaling—AKT1—thymus cancer	6.14e-05	0.00261	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB4—KIT—thymus cancer	6.08e-05	0.00258	CbGpPWpGaD
Gefitinib—MAP2K5—Integrin-mediated Cell Adhesion—AKT1—thymus cancer	6.04e-05	0.00257	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CYLD—thymus cancer	5.96e-05	0.00254	CbGpPWpGaD
Gefitinib—ERBB3—PI-3K cascade—AKT1—thymus cancer	5.92e-05	0.00252	CbGpPWpGaD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—IL2—thymus cancer	5.91e-05	0.00251	CbGpPWpGaD
Gefitinib—MAP2K5—ErbB1 downstream signaling—AKT1—thymus cancer	5.81e-05	0.00247	CbGpPWpGaD
Gefitinib—EGFR—Downstream signal transduction—KIT—thymus cancer	5.8e-05	0.00247	CbGpPWpGaD
Gefitinib—ERBB3—PI3K/AKT activation—AKT1—thymus cancer	5.78e-05	0.00246	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR—KIT—thymus cancer	5.77e-05	0.00246	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB2—KIT—thymus cancer	5.75e-05	0.00244	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—MAML2—thymus cancer	5.74e-05	0.00244	CbGpPWpGaD
Gefitinib—ERBB3—GAB1 signalosome—AKT1—thymus cancer	5.73e-05	0.00244	CbGpPWpGaD
Gefitinib—EGFR—DAP12 signaling—KIT—thymus cancer	5.72e-05	0.00243	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CYLD—thymus cancer	5.7e-05	0.00242	CbGpPWpGaD
Gefitinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KIT—thymus cancer	5.64e-05	0.0024	CbGpPWpGaD
Gefitinib—IRAK4—Regulation of toll-like receptor signaling pathway—AKT1—thymus cancer	5.61e-05	0.00239	CbGpPWpGaD
Gefitinib—ERBB3—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—thymus cancer	5.6e-05	0.00238	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by NGF—KIT—thymus cancer	5.48e-05	0.00233	CbGpPWpGaD
Gefitinib—EGFR—Signaling events mediated by PTP1B—AKT1—thymus cancer	5.47e-05	0.00233	CbGpPWpGaD
Gefitinib—EGFR—Fc epsilon receptor (FCERI) signaling—KIT—thymus cancer	5.38e-05	0.00229	CbGpPWpGaD
Gefitinib—EGFR—DAP12 interactions—KIT—thymus cancer	5.38e-05	0.00229	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR in disease—KIT—thymus cancer	5.38e-05	0.00229	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR—KIT—thymus cancer	5.33e-05	0.00227	CbGpPWpGaD
Gefitinib—CHEK2—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	5.31e-05	0.00226	CbGpPWpGaD
Gefitinib—EGFR—Rac1/Pak1/p38/MMP-2 pathway—TP53—thymus cancer	5.29e-05	0.00225	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR in Cancer—KIT—thymus cancer	5.28e-05	0.00225	CbGpPWpGaD
Gefitinib—EGFR—Signaling by PDGF—KIT—thymus cancer	5.26e-05	0.00224	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—IL2—thymus cancer	5.24e-05	0.00223	CbGpPWpGaD
Gefitinib—CSNK1E—Circadian rythm related genes—TP53—thymus cancer	5.18e-05	0.0022	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MAML2—thymus cancer	5.17e-05	0.0022	CbGpPWpGaD
Gefitinib—EGFR—Thromboxane A2 receptor signaling—AKT1—thymus cancer	5.15e-05	0.00219	CbGpPWpGaD
Gefitinib—EGFR—B Cell Activation—KIT—thymus cancer	4.98e-05	0.00212	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CYLD—thymus cancer	4.96e-05	0.00211	CbGpPWpGaD
Gefitinib—CHEK2—Cell Cycle—CDKN2A—thymus cancer	4.89e-05	0.00208	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—IL2—thymus cancer	4.8e-05	0.00204	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—CD8A—thymus cancer	4.8e-05	0.00204	CbGpPWpGaD
Gefitinib—IRAK1—Toll-like Receptor Signaling Pathway—AKT1—thymus cancer	4.77e-05	0.00203	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—KIT—thymus cancer	4.76e-05	0.00203	CbGpPWpGaD
Gefitinib—MAP2K5—MAPK Signaling Pathway—TP53—thymus cancer	4.72e-05	0.00201	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—KIT—thymus cancer	4.71e-05	0.002	CbGpPWpGaD
Gefitinib—CSNK1E—Cell Cycle, Mitotic—CDKN2A—thymus cancer	4.69e-05	0.00199	CbGpPWpGaD
Gefitinib—EGFR—LPA receptor mediated events—AKT1—thymus cancer	4.63e-05	0.00197	CbGpPWpGaD
Gefitinib—EGFR—AGE/RAGE pathway—AKT1—thymus cancer	4.52e-05	0.00192	CbGpPWpGaD
Gefitinib—MAP2K5—BDNF signaling pathway—AKT1—thymus cancer	4.51e-05	0.00192	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways in Glioblastoma—TP53—thymus cancer	4.5e-05	0.00191	CbGpPWpGaD
Gefitinib—EGFR—Rac1/Pak1/p38/MMP-2 pathway—AKT1—thymus cancer	4.47e-05	0.0019	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by SCF-KIT—AKT1—thymus cancer	4.42e-05	0.00188	CbGpPWpGaD
Gefitinib—EGFR—Regulation of Telomerase—AKT1—thymus cancer	4.41e-05	0.00188	CbGpPWpGaD
Gefitinib—ERBB3—Disease—MAML2—thymus cancer	4.37e-05	0.00186	CbGpPWpGaD
Gefitinib—ERBB3—Downstream signaling of activated FGFR—AKT1—thymus cancer	4.23e-05	0.0018	CbGpPWpGaD
Gefitinib—ABCG2—HIF-1-alpha transcription factor network—AKT1—thymus cancer	4.22e-05	0.00179	CbGpPWpGaD
Gefitinib—CSNK1E—Cell Cycle—CDKN2A—thymus cancer	4.19e-05	0.00178	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by ERBB4—AKT1—thymus cancer	4.16e-05	0.00177	CbGpPWpGaD
Gefitinib—MAP2K5—Insulin Signaling—AKT1—thymus cancer	4.15e-05	0.00176	CbGpPWpGaD
Gefitinib—MAP2K5—EGF/EGFR Signaling Pathway—AKT1—thymus cancer	4.11e-05	0.00175	CbGpPWpGaD
Gefitinib—CSNK1E—TCF dependent signaling in response to WNT—AKT1—thymus cancer	4.1e-05	0.00174	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MAML2—thymus cancer	4.02e-05	0.00171	CbGpPWpGaD
Gefitinib—MAP2K5—MAPK Signaling Pathway—AKT1—thymus cancer	3.99e-05	0.0017	CbGpPWpGaD
Gefitinib—ERBB3—Downstream signal transduction—AKT1—thymus cancer	3.98e-05	0.00169	CbGpPWpGaD
Gefitinib—CSNK1E—RNF mutants show enhanced WNT signaling and proliferation—AKT1—thymus cancer	3.97e-05	0.00169	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by FGFR—AKT1—thymus cancer	3.96e-05	0.00168	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by ERBB2—AKT1—thymus cancer	3.94e-05	0.00168	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—IL2—thymus cancer	3.92e-05	0.00167	CbGpPWpGaD
Gefitinib—ERBB3—DAP12 signaling—AKT1—thymus cancer	3.92e-05	0.00167	CbGpPWpGaD
Gefitinib—ERBB3—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	3.86e-05	0.00164	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways in Glioblastoma—AKT1—thymus cancer	3.8e-05	0.00162	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—KIT—thymus cancer	3.75e-05	0.0016	CbGpPWpGaD
Gefitinib—IRAK1—Regulation of toll-like receptor signaling pathway—AKT1—thymus cancer	3.72e-05	0.00158	CbGpPWpGaD
Gefitinib—ERBB3—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	3.69e-05	0.00157	CbGpPWpGaD
Gefitinib—ERBB3—DAP12 interactions—AKT1—thymus cancer	3.69e-05	0.00157	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by FGFR in disease—AKT1—thymus cancer	3.69e-05	0.00157	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling by WNT in cancer—AKT1—thymus cancer	3.68e-05	0.00157	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—KIT—thymus cancer	3.66e-05	0.00156	CbGpPWpGaD
Gefitinib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—AKT1—thymus cancer	3.66e-05	0.00156	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by EGFR—AKT1—thymus cancer	3.65e-05	0.00155	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD8A—thymus cancer	3.65e-05	0.00155	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—IL2—thymus cancer	3.64e-05	0.00155	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by EGFR in Cancer—AKT1—thymus cancer	3.62e-05	0.00154	CbGpPWpGaD
Gefitinib—MAP2K5—Focal Adhesion—AKT1—thymus cancer	3.61e-05	0.00154	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by PDGF—AKT1—thymus cancer	3.61e-05	0.00153	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—KIT—thymus cancer	3.61e-05	0.00153	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—CD4—thymus cancer	3.6e-05	0.00153	CbGpPWpGaD
Gefitinib—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thymus cancer	3.6e-05	0.00153	CbGpPWpGaD
Gefitinib—EGFR—Androgen receptor signaling pathway—AKT1—thymus cancer	3.56e-05	0.00151	CbGpPWpGaD
Gefitinib—ERBB3—B Cell Activation—AKT1—thymus cancer	3.41e-05	0.00145	CbGpPWpGaD
Gefitinib—MKNK1—Disease—KIT—thymus cancer	3.41e-05	0.00145	CbGpPWpGaD
Gefitinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	3.39e-05	0.00144	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—TP53—thymus cancer	3.36e-05	0.00143	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CYLD—thymus cancer	3.32e-05	0.00141	CbGpPWpGaD
Gefitinib—EGFR—PI-3K cascade—AKT1—thymus cancer	3.29e-05	0.0014	CbGpPWpGaD
Gefitinib—ERBB3—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	3.27e-05	0.00139	CbGpPWpGaD
Gefitinib—EGFR—PI3K/AKT activation—AKT1—thymus cancer	3.22e-05	0.00137	CbGpPWpGaD
Gefitinib—EGFR—GAB1 signalosome—AKT1—thymus cancer	3.19e-05	0.00136	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MAML2—thymus cancer	3.18e-05	0.00135	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—KIT—thymus cancer	3.13e-05	0.00133	CbGpPWpGaD
Gefitinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—thymus cancer	3.12e-05	0.00133	CbGpPWpGaD
Gefitinib—EGFR—ErbB1 downstream signaling—AKT1—thymus cancer	3.12e-05	0.00133	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—TP53—thymus cancer	3.08e-05	0.00131	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MAML2—thymus cancer	3.06e-05	0.0013	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling by Wnt—AKT1—thymus cancer	3.04e-05	0.00129	CbGpPWpGaD
Gefitinib—EGFR—Direct p53 effectors—TP53—thymus cancer	2.93e-05	0.00125	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD8A—thymus cancer	2.91e-05	0.00124	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—CD4—thymus cancer	2.87e-05	0.00122	CbGpPWpGaD
Gefitinib—EGFR—Integrated Breast Cancer Pathway—TP53—thymus cancer	2.76e-05	0.00117	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—CD4—thymus cancer	2.76e-05	0.00117	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—KIT—thymus cancer	2.74e-05	0.00117	CbGpPWpGaD
Gefitinib—CHEK2—Cell Cycle—TP53—thymus cancer	2.72e-05	0.00116	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD8A—thymus cancer	2.67e-05	0.00114	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—KIT—thymus cancer	2.65e-05	0.00113	CbGpPWpGaD
Gefitinib—MKNK1—Disease—CD4—thymus cancer	2.61e-05	0.00111	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling by NGF—AKT1—thymus cancer	2.61e-05	0.00111	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAML2—thymus cancer	2.55e-05	0.00108	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—TP53—thymus cancer	2.53e-05	0.00108	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—AKT1—thymus cancer	2.52e-05	0.00107	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by NGF—AKT1—thymus cancer	2.51e-05	0.00107	CbGpPWpGaD
Gefitinib—EGFR—Signaling by SCF-KIT—AKT1—thymus cancer	2.46e-05	0.00105	CbGpPWpGaD
Gefitinib—EGFR—Disease—MAML2—thymus cancer	2.43e-05	0.00104	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD8A—thymus cancer	2.42e-05	0.00103	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—CD4—thymus cancer	2.39e-05	0.00102	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—KIT—thymus cancer	2.39e-05	0.00101	CbGpPWpGaD
Gefitinib—EGFR—Downstream signaling of activated FGFR—AKT1—thymus cancer	2.36e-05	0.001	CbGpPWpGaD
Gefitinib—CSNK1E—Cell Cycle—TP53—thymus cancer	2.33e-05	0.000993	CbGpPWpGaD
Gefitinib—EGFR—Integrated Breast Cancer Pathway—AKT1—thymus cancer	2.33e-05	0.000991	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB4—AKT1—thymus cancer	2.32e-05	0.000986	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	2.29e-05	0.000973	CbGpPWpGaD
Gefitinib—ABCB1—HIF-1-alpha transcription factor network—AKT1—thymus cancer	2.28e-05	0.00097	CbGpPWpGaD
Gefitinib—EGFR—Downstream signal transduction—AKT1—thymus cancer	2.21e-05	0.000942	CbGpPWpGaD
Gefitinib—EGFR—EGF/EGFR Signaling Pathway—AKT1—thymus cancer	2.2e-05	0.000937	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR—AKT1—thymus cancer	2.2e-05	0.000937	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB2—AKT1—thymus cancer	2.19e-05	0.000933	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—KIT—thymus cancer	2.19e-05	0.00093	CbGpPWpGaD
Gefitinib—EGFR—DAP12 signaling—AKT1—thymus cancer	2.18e-05	0.000928	CbGpPWpGaD
Gefitinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	2.15e-05	0.000915	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—AKT1—thymus cancer	2.14e-05	0.00091	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD4—thymus cancer	2.1e-05	0.000892	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by NGF—AKT1—thymus cancer	2.09e-05	0.000889	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—KIT—thymus cancer	2.09e-05	0.000889	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR in disease—AKT1—thymus cancer	2.05e-05	0.000873	CbGpPWpGaD
Gefitinib—EGFR—DAP12 interactions—AKT1—thymus cancer	2.05e-05	0.000873	CbGpPWpGaD
Gefitinib—EGFR—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	2.05e-05	0.000873	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR—AKT1—thymus cancer	2.03e-05	0.000865	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—CD4—thymus cancer	2.03e-05	0.000862	CbGpPWpGaD
Gefitinib—ERBB3—Disease—KIT—thymus cancer	2.02e-05	0.000859	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR in Cancer—AKT1—thymus cancer	2.02e-05	0.000858	CbGpPWpGaD
Gefitinib—EGFR—Signaling by PDGF—AKT1—thymus cancer	2.01e-05	0.000854	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—KIT—thymus cancer	2.01e-05	0.000854	CbGpPWpGaD
Gefitinib—EGFR—Focal Adhesion—AKT1—thymus cancer	1.94e-05	0.000825	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	1.93e-05	0.000822	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IL2—thymus cancer	1.93e-05	0.000821	CbGpPWpGaD
Gefitinib—EGFR—B Cell Activation—AKT1—thymus cancer	1.9e-05	0.000808	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—KIT—thymus cancer	1.86e-05	0.000789	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—IL2—thymus cancer	1.83e-05	0.000777	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—KIT—thymus cancer	1.82e-05	0.000774	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	1.82e-05	0.000773	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—AKT1—thymus cancer	1.8e-05	0.000764	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAML2—thymus cancer	1.7e-05	0.000725	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—IL2—thymus cancer	1.68e-05	0.000714	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD4—thymus cancer	1.67e-05	0.000711	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD8A—thymus cancer	1.62e-05	0.00069	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CD4—thymus cancer	1.6e-05	0.00068	CbGpPWpGaD
Gefitinib—ERBB3—Disease—CD4—thymus cancer	1.54e-05	0.000657	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL2—thymus cancer	1.54e-05	0.000654	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD4—thymus cancer	1.54e-05	0.000653	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KIT—thymus cancer	1.47e-05	0.000624	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—AKT1—thymus cancer	1.43e-05	0.000609	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KIT—thymus cancer	1.41e-05	0.000601	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—AKT1—thymus cancer	1.4e-05	0.000595	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD4—thymus cancer	1.39e-05	0.000592	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—AKT1—thymus cancer	1.38e-05	0.000585	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL2—thymus cancer	1.31e-05	0.000555	CbGpPWpGaD
Gefitinib—MKNK1—Disease—AKT1—thymus cancer	1.3e-05	0.000553	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL2—thymus cancer	1.28e-05	0.000545	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KIT—thymus cancer	1.22e-05	0.000518	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—AKT1—thymus cancer	1.19e-05	0.000507	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KIT—thymus cancer	1.18e-05	0.000501	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	1.15e-05	0.000491	CbGpPWpGaD
Gefitinib—EGFR—Disease—KIT—thymus cancer	1.12e-05	0.000478	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TP53—thymus cancer	1.08e-05	0.000459	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—AKT1—thymus cancer	1.05e-05	0.000445	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL2—thymus cancer	1.03e-05	0.000439	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—AKT1—thymus cancer	1.01e-05	0.00043	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL2—thymus cancer	9.95e-06	0.000423	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—AKT1—thymus cancer	9.9e-06	0.000421	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	9.75e-06	0.000415	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—IL2—thymus cancer	9.41e-06	0.0004	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL2—thymus cancer	9.38e-06	0.000399	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD4—thymus cancer	9.31e-06	0.000396	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—AKT1—thymus cancer	9.1e-06	0.000387	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—AKT1—thymus cancer	9.03e-06	0.000384	CbGpPWpGaD
Gefitinib—EGFR—Disease—CD4—thymus cancer	8.6e-06	0.000366	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL2—thymus cancer	8.57e-06	0.000364	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—thymus cancer	8.38e-06	0.000357	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—AKT1—thymus cancer	8.34e-06	0.000355	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL2—thymus cancer	8.28e-06	0.000352	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—AKT1—thymus cancer	7.98e-06	0.000339	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KIT—thymus cancer	7.87e-06	0.000335	CbGpPWpGaD
Gefitinib—ERBB3—Disease—AKT1—thymus cancer	7.7e-06	0.000328	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—AKT1—thymus cancer	7.66e-06	0.000326	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AKT1—thymus cancer	7.08e-06	0.000301	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—AKT1—thymus cancer	6.95e-06	0.000295	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—thymus cancer	6.63e-06	0.000282	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—thymus cancer	6.39e-06	0.000272	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—thymus cancer	6.04e-06	0.000257	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKT1—thymus cancer	5.6e-06	0.000238	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL2—thymus cancer	5.54e-06	0.000236	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKT1—thymus cancer	5.39e-06	0.000229	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—thymus cancer	5.32e-06	0.000226	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—AKT1—thymus cancer	5.1e-06	0.000217	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKT1—thymus cancer	5.08e-06	0.000216	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AKT1—thymus cancer	4.65e-06	0.000198	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKT1—thymus cancer	4.49e-06	0.000191	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKT1—thymus cancer	4.29e-06	0.000182	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—thymus cancer	3.56e-06	0.000151	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AKT1—thymus cancer	3.35e-06	0.000143	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT1—thymus cancer	3e-06	0.000128	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AKT1—thymus cancer	2.4e-06	0.000102	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKT1—thymus cancer	2.27e-06	9.65e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKT1—thymus cancer	2.07e-06	8.8e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKT1—thymus cancer	1.86e-06	7.9e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKT1—thymus cancer	1.81e-06	7.71e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKT1—thymus cancer	1.71e-06	7.27e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKT1—thymus cancer	1.69e-06	7.2e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKT1—thymus cancer	1.12e-06	4.75e-05	CbGpPWpGaD
